Tumour-Infiltrating Lymphocytes (TILs) and PD-L1 Expression Correlate with Lymph Node Metastasis, High-Grade Transformation and Shorter Metastasis-Free Survival in Patients with Acinic Cell Carcinoma (AciCC) of the Salivary Glands.
PD-L1
acinic cell carcinoma
checkpoint inhibition
immuno-oncology
tumour-infiltrating lymphocytes
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
25 Feb 2021
25 Feb 2021
Historique:
received:
18
01
2021
revised:
12
02
2021
accepted:
21
02
2021
entrez:
6
3
2021
pubmed:
7
3
2021
medline:
7
3
2021
Statut:
epublish
Résumé
The aim of this study was to assess the number of tumour-infiltrating lymphocytes (TILs) and the expression of This single centre retrospective study represents a cohort of 36 primary AciCCs with long-term clinical follow-up. Immunohistochemically defined immune cell subtypes, i.e., those expressing T-cell markers (CD3, CD4 and CD8) or a B-cell marker (CD20) were characterized on tumour tissue sections. The number of TILs was quantitatively evaluated using software for digital bioimage analysis (QuPath). PD-L1 expression on the tumour cells and on immune cells was assessed immunohistochemically employing established scoring criteria: tumour proportion score (TPS), Ventana immune cell score (IC-Score) and combined positive score (CPS). Higher numbers of tumour-infiltrating T- and B-lymphocytes were significantly associated with high-grade transformation. Furthermore, higher counts of T-lymphocytes correlated with node-positive disease. There was a significant correlation between higher levels of PD-L1 expression and lymph node metastases as well as the occurrence of high-grade transformation. Moreover, PD-L1 CPS was associated with poor prognosis regarding metastasis-free survival ( The current study is the first to demonstrate an association between PD-L1 expression and lymph node metastases as well as grading in AciCCs. In conclusion, increased immune cell infiltration of T and B cells as well as higher levels of PD-L1 expression in AciCC in association with high-grade transformation, lymph node metastasis and unfavourable prognosis suggests a relevant interaction between tumour cells and immune cell infiltrates in a subset of AciCCs, and might represent a rationale for immune checkpoint inhibition.
Identifiants
pubmed: 33669038
pii: cancers13050965
doi: 10.3390/cancers13050965
pmc: PMC7956490
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Nat Commun. 2019 Jan 21;10(1):368
pubmed: 30664630
Am J Surg Pathol. 2019 Sep;43(9):1264-1272
pubmed: 31094928
Cancer J. 2018 Jan/Feb;24(1):41-46
pubmed: 29360727
J Laryngol Otol. 1979 Apr;93(4):325-40
pubmed: 438614
Oral Oncol. 2020 Dec;111:104931
pubmed: 32736208
Immunol Res. 2013 Dec;57(1-3):115-24
pubmed: 24293009
J Oral Pathol Med. 2018 Aug;47(7):683-690
pubmed: 29719073
Oral Oncol. 2012 Oct;48(10):991-996
pubmed: 22694907
Genes Cancer. 2018 May;9(5-6):176-189
pubmed: 30603054
Sci Rep. 2019 Sep 4;9(1):12724
pubmed: 31484986
Oral Oncol. 2018 Jul;82:53-60
pubmed: 29909902
J Otolaryngol Head Neck Surg. 2015 Oct 29;44:43
pubmed: 26515170
Int J Radiat Oncol Biol Phys. 2021 Jan 1;109(1):134-144
pubmed: 32781104
Clin Cancer Res. 2020 Feb 15;26(4):837-845
pubmed: 31796519
JAMA Otolaryngol Head Neck Surg. 2013 Nov;139(11):1195-202
pubmed: 24076756
Oral Oncol. 2002 Oct;38(7):706-13
pubmed: 12167424
Cancers (Basel). 2020 Apr 03;12(4):
pubmed: 32260165
Trends Cancer. 2016 Dec;2(12):747-757
pubmed: 28626801
Am J Surg Pathol. 2009 Aug;33(8):1137-45
pubmed: 19461506
Cancer. 2009 May 15;115(10):2128-37
pubmed: 19309749
Annu Rev Immunol. 2019 Apr 26;37:173-200
pubmed: 30550719
Head Neck Pathol. 2016 Jun;10(2):152-60
pubmed: 26245749
Oral Oncol. 2019 Jan;88:95-101
pubmed: 30616805
Ann Oncol. 2016 Aug;27(8):1492-504
pubmed: 27207108
Eur Arch Otorhinolaryngol. 2020 Oct;277(10):2673-2679
pubmed: 32367151
J Surg Oncol. 2016 Jul;114(1):36-43
pubmed: 27111278
Hematol Oncol Stem Cell Ther. 2009;2(1):259-64
pubmed: 20063555
Oncotarget. 2015 Sep 29;6(29):27359-77
pubmed: 26318293
Am J Surg. 2003 Jul;186(1):57-62
pubmed: 12842751
J Clin Med. 2019 Aug 27;8(9):
pubmed: 31461946
J Immunol. 2018 Jan 15;200(2):385-391
pubmed: 29311379
Trends Biochem Sci. 2018 Dec;43(12):1014-1032
pubmed: 30287140
Head Neck Pathol. 2020 Sep;14(3):593-597
pubmed: 31541432
Front Immunol. 2019 Nov 07;10:2550
pubmed: 31787969
Clin Cancer Res. 2020 Jun 15;26(12):2859-2870
pubmed: 32060100
Annu Rev Immunol. 2016 May 20;34:539-73
pubmed: 26927206
Am J Cancer Res. 2020 Mar 01;10(3):727-742
pubmed: 32266087
Onco Targets Ther. 2017 Jun 13;10:2983-2992
pubmed: 28652780
Cancer Immunol Immunother. 2020 Jul;69(7):1363-1373
pubmed: 32232506
Otolaryngol Head Neck Surg. 2016 Jan;154(1):121-30
pubmed: 26419838
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Pathologe. 2018 Nov;39(6):498-519
pubmed: 30367225
Cancer Immunol Res. 2016 Aug;4(8):679-87
pubmed: 27312343
Gen Diagn Pathol. 1996 Oct;142(2):75-81
pubmed: 8950571
Cancer. 1983 Aug 1;52(3):542-9
pubmed: 6861091
Head Neck. 2021 Mar;43(3):768-777
pubmed: 33169486
Otolaryngol Head Neck Surg. 1988 Feb;98(2):155-61
pubmed: 3128758
Am J Clin Oncol. 2018 Nov;41(11):1083-1088
pubmed: 29462123
BMC Cancer. 2018 Feb 6;18(1):156
pubmed: 29409471
HNO. 2001 Oct;49(10):825-30
pubmed: 11699143
Ann Surg Oncol. 2015 Nov;22(12):4014-9
pubmed: 25743328
Acta Otolaryngol. 2020 Feb;140(2):175-180
pubmed: 31944154